In addition to genetically modified immune cells, the use of tumour-infiltrating lymphocyte therapy has demonstrated a robust clinical response in patients with tumour types such as melanoma where other treatments such as anti-PD-1 therapy have failed, making it another treatment option that can be explored. This evidence concerns the gene PDCD1 and neoplasm.